Calcitonin Gene Related Peptide (CGRP) - Pipeline Review, H1 2018

**Publication ID:**
GMD0318051

**Publication Date:**
March 13, 2018

**Pages:**
62

**Publisher:**
Global Markets Direct

**Region:**
Global [1]

$3,500.00

Publication License Type *
- Single User License (PDF), $3,500.00
- Site License (PDF), $7,000.00
- Global License (PDF), $10,500.00

Please choose the suitable license type from above. More details are at given under tab "Report License Types" below.
Description:
Calcitonin Gene Related Peptide (CGRP) - Pipeline Review, H1 2018

Summary

According to the recently published report 'Calcitonin Gene Related Peptide (CGRP) - Pipeline Review, H1 2018'; Calcitonin Gene Related Peptide (CGRP) pipeline Target constitutes close to 7 molecules. Out of which approximately 7 molecules are developed by Companies.

Calcitonin Gene Related Peptide (CGRP) - Calcitonin gene related peptide (CGRP) is a member of the calcitonin family of peptides. It exists in two forms alpha-CGRP and beta-CGRP. CGRP is produced in both peripheral and central neurons. CGRP is derived mainly from the cell bodies of motor neurons when synthesized in the ventral horn of the spinal cord and contribute to the regeneration of nervous tissue after injury.

CGRP is derived from dorsal root ganglion when synthesized in the dorsal horn of the spinal cord and linked to the transmission of pain. CGRP also plays an important role in cardiovascular homeostasis and nociception.

The report 'Calcitonin Gene Related Peptide (CGRP) - Pipeline Review, H1 2018' outlays comprehensive information on the Calcitonin Gene Related Peptide (CGRP) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Calcitonin Gene Related Peptide (CGRP) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Preclinical and Discovery stages are 2, 1, 2 and 2 respectively. Report covers products from therapy areas Central Nervous System which include indications Migraine, Cluster Headache Syndrome, Dental Pain, Inflammatory Pain, Osteoarthritis Pain and Pain.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Calcitonin Gene Related Peptide (CGRP)
- The report reviews Calcitonin Gene Related Peptide (CGRP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental
activities
- The report reviews key players involved in Calcitonin Gene Related Peptide (CGRP) targeted therapeutics and enlists all their major and minor projects
- The report assesses Calcitonin Gene Related Peptide (CGRP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Calcitonin Gene Related Peptide (CGRP) targeted therapeutics

Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Calcitonin Gene Related Peptide (CGRP)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Calcitonin Gene Related Peptide (CGRP) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table Of Contents:
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Calcitonin Gene Related Peptide (CGRP) - Overview
Calcitonin Gene Related Peptide (CGRP) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Calcitonin Gene Related Peptide (CGRP) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Calcitonin Gene Related Peptide (CGRP) - Companies Involved in Therapeutics Development
Alder Biopharmaceuticals Inc
Eli Lilly and Co
Serometrix LLC
Teva Pharmaceutical Industries Ltd
Calcitonin Gene Related Peptide (CGRP) - Drug Profiles
AFAP-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
eptinezumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fremanezumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
galcanezumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NOXL-41 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CGRP for Migraine and Osteoarthritis Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CGRP for Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Calcitonin Gene Related Peptide (CGRP) - Dormant Products
Calcitonin Gene Related Peptide (CGRP) - Discontinued Products
Calcitonin Gene Related Peptide (CGRP) - Product Development Milestones
Featured News & Press Releases
Feb 02, 2018: European Medicines Agency (EMA) Accepts Fremanezumab Marketing Authorization Application
Jan 08, 2018: Alder Announces Eptinezumab Significantly Reduces Migraine Risk Meets Primary and All Key Secondary Endpoints in Pivotal PROMISE 2 Phase 3 Trial for Chronic Migraine Prevention
Dec 18, 2017: FDA Accepts Biologics License Application for Fremanezumab with Priority Review for Prevention of Migraine and Grants Fast Track Designation for Cluster Headache Development Program
Dec 11, 2017: FDA Accepts Biologics License Application to Review Galcanezumab for the Prevention of Migraine in Adults
Nov 29, 2017: The New England Journal of Medicine Publishes Data from Pivotal Phase III Trial of Fremanezumab for the Preventive Treatment of Chronic Migraine
Oct 17, 2017: Teva Announces Submission of Biologics License Application for Fremanezumab to the U.S. FDA
Sep 09, 2017: Teva Showcases Data Demonstrating Potential of Fremanezumab to Address Significant Unmet Need in Patients with Chronic and Episodic Migraine
Sep 08, 2017: IHC 2017: Lilly’s Galcanezumab Demonstrates Positive Long-Term Safety Results For Up To 12 Months In Patients With Migraine
Sep 07, 2017: Alder BioPharmaceuticals to Present Data from Eptinezumab Development Program at 18th Congress of the International Headache Society
Sep 06, 2017: Lilly To Present New Data For Galcanezumab At The 18th Congress Of The International Headache Society
Sep 05, 2017: Teva to Present Fremanezumab Data on Migraine Prevention at the 18th Congress of the International Headache Society
Jun 27, 2017: Alder BioPharmaceuticals Announces Positive Eptinezumab Phase 3 Results for Prevention of Frequent Episodic Migraine
Jun 10, 2017: Lilly’s Galcanezumab Significantly Reduces Number Of Migraine Headache Days For Patients With Migraine: New Results Presented At AHS
Jun 08, 2017: Lilly To Present Late-Breaking Data For Galcanezumab At The American Headache Society Annual Scientific Meeting
Jun 07, 2017: Alder to Present Migraine Prevention Data for Eptinezumab at 59th Annual Scientific Meeting of the American Headache Society
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
List of Tables
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Alder Biopharmaceuticals Inc, H1 2018
Pipeline by Eli Lilly and Co, H1 2018
Pipeline by Serometrix LLC, H1 2018
Pipeline by Teva Pharmaceutical Industries Ltd, H1 2018
Dormant Projects, H1 2018
Discontinued Products, H1 2018

List of Figures
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

Companies Mentioned:
Alder Biopharmaceuticals Inc
Eli Lilly and Co
Serometrix LLC
Teva Pharmaceutical Industries Ltd

License Types:

**Single User License (PDF)**

- This license allows for use of a publication by one person.
- This person may print out a single copy of the publication.
- This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- This person cannot share the publication (or any information contained therein) with any other person or persons.
• Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
• Customers who infringe these license terms are liable for a Global license fee.

**Site License (PDF)**

• This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
• These users may print out a single copy of the publication.
• These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
• These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
• Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
• Customers who infringe these license terms are liable for a Global license fee.

**Global License (PDF)**

• This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
• Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
• These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.